Alloplex Biotherapeutics is an angel funded private biotechnology company dedicated to the goal of developing an off-the-shelf anti-tumor vaccine. Our approach involves genetically engineering an allogeneic tumor cell line to express an optimal set of proprietary immunomodulatory gene cassettes intended to enhance discrete immunologic functions. We are employing an all human in vitro assay to efficiently select and optimize vaccine candidates for our lead melanoma indication. By avoiding artifact prone preclinical animal models, we expect to improve the likelihood that the in vitro results will translate to the clinical setting. This approach is the basis of a platform technology with applicability across multiple tumor types and is also ideally suited for combination with the checkpoint inhibitor class of biologics that have recently become the standard-of-care in melanoma. We anticipate initiating a small Phase I trial by end of 2019 with the goal of demonstrating enhanced anti-tumor reactivity in peripheral blood cells in the context of a benign safety profile. Additional larger registration trials will be focused on achieving meaningful improvements in the standard efficacy endpoints of progression-free survival and overall survival.